However, to date there is only limited clinical evidence on SGLT2 inhibitor monotherapy, relative to other glucose-lowering agents, in patients with T2D (drug-naïve), irrespective of their CHF history. The gene discussed is SLC5A2; the disease is congestive heart failure.